CogState Stock

CogState FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of CogState (CGS.AX) as of Sep 3, 2026 is 82.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 71.49 % — a change of 15.83% (higher).

FCF Conversion

82.81 %

YoY

15.83%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of CogState is 2026 82.81 % . FCF Conversion Rate (FCF/EBITDA) of CogState was 2025 71.49 % . It decreases by 15.83% higher compared to the previous year.

The CogState FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
527.90 USD
Jan 1, 2019
100.21 USD
Jan 1, 2020
122.98 USD
Jan 1, 2021
245.69 USD
Jan 1, 2022
81.98 USD
Jan 1, 2023
-43.62 USD
Jan 1, 2024
71.49 USD
Jan 1, 2025
82.81 USD
The CogState FCF Conversion history
YEARFCF ConversionYoY
82.81 %+15.83%
71.49 %-263.88%
-43.62 %-153.21%
81.98 %-66.63%
245.69 %+99.78%
122.98 %+22.73%
100.21 %-81.02%
527.90 %-363.71%
-200.19 %-674.34%
34.86 %-53.96%
75.70 %-30.35%
108.68 %
Access this data via the Eulerpool API

CogState Stock analysis

What does CogState do? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CogState stock

FCF Conversion Rate (FCF/EBITDA) of CogState is 82.81 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of CogState changed from 71.49 % to 82.81 %, representing a 15.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) CogState since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s CogState with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — CogState

All Key Metrics — CogState